PSR ENT base

  • Research type

    Research Study

  • Full title

    Ear, Nose & Throat (ENT) Product Surveillance Registry (PSR) platform base clinical investigation plan PROPEL Drug-Eluting Sinus Stent Family Addendum

  • IRAS ID

    324422

  • Contact name

    Hesham Saleh

  • Contact email

    h.saleh@imperial.ac.uk

  • Sponsor organisation

    Medtronic Inc.

  • Duration of Study in the UK

    2 years, 4 months, 13 days

  • Research summary

    The PSR registry is an ongoing record of the experience from people around the world treated with a Medtronic product and its performance. It will be used to support post-market surveillance activities and post-approval studies, e.g. to collect safety and performance information as required by regulations applicable to Medtronic. In addition, it will be used to obtain clinical evidence for the development and improvement of medical devices, therapies, device guidelines, patient services/solutions and provide clinical data to support health economics and clinical outcomes research.

    The registry is not an experimental clinical study. For this registry, we will only be collecting data, assessed in a "real-life" environment and therefore the duration of data collection will be determined by the product received by the patient.

    This submission is for patients who have been, or are due to be, treated with a Medtronic market-approved Ear, nose & Throat (ENT) device (PSR Surgical Base CIP).

    The first accompanying addendum for the ENT base protocol is the PROPEL Drug-Eluting Sinus Stent Family, to confirm the long-term clinical safety and
    performance, acceptability of identified risks, and to detect emerging risks based
    on factual evidence for the PROPEL family of products when used according to
    labeling (in patients with chronic rhinosinusitis (CRS) undergoing sinus surgery). Additionally, this study
    intends to collect data on use of corticosteroid-eluting implants in the European
    CRS population. Data collected will be used to ensure continued consistency
    between clinical data, the information materials supplied by the manufacturer, and
    the risk management documentation.

  • REC name

    East Midlands - Leicester South Research Ethics Committee

  • REC reference

    23/EM/0081

  • Date of REC Opinion

    20 Apr 2023

  • REC opinion

    Further Information Favourable Opinion